Anti-Human IGF1 Recombinant Antibody (BI 836845) (CAT#: TAB-385CL)

Figure 1 Treatment with 100 nmol/L rapamycin for 24 hours increased AKT Ser473-phosphorylation, which was inhibited by the addition of 100 nmol/L BI 836845.

Friedbichler, K., Hofmann, M. H., Kroez, M., Ostermann, E., Lamche, H. R., Koessl, C., ... & Adam, P. J. (2014). Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Molecular cancer therapeutics, 13(2), 399-409.

Figure 2 Comprehensive preclinical characterization of the pharmacodynamic properties of BI 836845 in growing rats.

BI 836845 treatment led to elevated total IGF-I levels in the plasma, which returned to baseline during the recovery period. During treatment all doses showed highly significant effects compared with control animals, with the peak increase for 60 and 200 mg/kg being greater than that seen with 20 mg/kg.

Friedbichler, K., Hofmann, M. H., Kroez, M., Ostermann, E., Lamche, H. R., Koessl, C., ... & Adam, P. J. (2014). Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Molecular cancer therapeutics, 13(2), 399-409.

Figure 3 Enhanced in vivo antitumor efficacy of BI 836845 in combination with rapamycin in the RD-ES xenograft model.

Treatment of mice bearing RD-ES tumors with BI 836845 (twice weekly, 100 mg/kg i.p.) or rapamycin (5 x weekly, 5 mg/kg i.p.) led to a TGl of 53% and 75%, respectively, compared with control animals (0.5% Natrosol, 10 mL/kg i.p. daily). Combining these agents improved efficacy (93% TGI).

Friedbichler, K., Hofmann, M. H., Kroez, M., Ostermann, E., Lamche, H. R., Koessl, C., ... & Adam, P. J. (2014). Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Molecular cancer therapeutics, 13(2), 399-409.